At the recent Annual American Society of Clinical Oncology (ASCO) Meeting, bluebird bio, Inc. released updated data from its Phase 1 trial of bb2121. bb2121 is a new anti-BCMA chimeric antigen receptor (CAR) T cell therapy option for patients who have relapsed or refractory multiple myeloma.
The first round of data was released in November of last year, and since then, bluebird bio, Inc. has obtained new data on the same patients after longer follow-up, as well as efficacy and safety data on 9 more patients who were subsequently treated.
In total, 18 patients with relapsed/refractory multiple myeloma were measured, and objectively speaking, it was found that all patients had a positive response to the bb2121 therapy and further, no myeloma progression, even those who had a high tumor burden or were heavily pretreated.
The multiple myeloma patients in this relapsed/refractory category currently have few, if any, effective treatment options, so these data are extremely important to the medical community in general.
David Davidson, the chief medical officer behind the trial, said,
“These data will advance our understanding of the bb2121 risk-benefit profile and inform planning with our partners at Celgene for the dose expansion cohort of this study, and the design of a potential pivotal study.”
Even though bb2121 is in the early stages of development and approval, keep it on your radar in the coming months.
It is giving previously untreatable patients hope!